Ambulatory systolic blood pressure predicts left ventricular mass in type 2 diabetes, independent of central systolic blood pressure

Blood Pressure Monitoring

Volumn 17, Issue 4, 2012, Pages 139-144

  Wijkman, Magnus ^a   Länne, Toste ^a   Grodzinsky, Ewa ^b,c   Ä stgren, Carl Johan ^a   Engvall, Jan ^a   Nystrom, Fredrik H ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Society and Welfare   (Sweden)

^c Unit of Research and Development in Local Health Care   (Sweden)

Author keywords

ambulatory blood pressure; central blood pressure; hypertension; left ventricular hypertrophy; target organ damage; type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; ORAL ANTIDIABETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; CENTRAL SYSTOLIC BLOOD PRESSURE; CIRCADIAN RHYTHM; CORRELATION ANALYSIS; DISEASE DURATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

AGED; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; DIABETES MELLITUS, TYPE 2; FEMALE; HEART RATE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES;

EID: 84863855990     PISSN: 13595237     EISSN: 14735725     Source Type: Journal    
DOI: 10.1097/MBP.0b013e328355fdfb     Document Type: Article

References (30)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322
2. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
3. Verdecchia P, Schillaci G, Borgioni C, Gattobigio R, Ambrosio G, Porcellati C. Prevalent influence of systolic over pulse pressure on left ventricular mass in essential hypertension. Eur Heart J 2002; 23:658-665.
4. Roman MJ, Okin PM, Kizer JR, Lee ET, Howard BV, Devereux RB. Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. J Hypertens 2010; 28:384-388.
5. Cuspidi C, Lonati L, Sampieri L, Macca G, Michev I, Salerno M, et al. Impact of blood pressure control on prevalence of left ventricular hypertrophy in treated hypertensive patients. Cardiology 2000; 93:149-154.
6. Schillaci G, Verdecchia P, Sacchi N, Bruni B, Benemio G, Pede S, et al. Clinical relevance of office underestimation of usual blood pressure in treated hypertension. Am J Hypertens 2000; 13:523-528.
7. Sharman JE, Fang ZY, Haluska B, Stowasser M, Prins JB, Marwick TH. Left ventricular mass in patients with type 2 diabetes is independently associated with central but not peripheral pulse pressure. Diabetes Care 2005; 28:937-939.
8. Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens 2009; 27:461-467.
9. Devereux RB, Roman MJ, Paranicas M, OGrady MJ, Lee ET,Welty TK, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000; 101:2271-2276.
10. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation 2001; 103:102-107.
11. Wijkman M, Lanne T, Engvall J, Lindstrom T, Ostgren CJ, Nystrom FH. Masked nocturnal hypertension - a novel marker of risk in type 2 diabetes. Diabetologia 2009; 52:1258-1264.
12. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111:697-716.
13. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618.
14. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
15. Hoelzel W,Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50:166-174.
16. Huang CM, Wang KL, Cheng HM, Chuang SY, Sung SH, Yu WC, et al. Central versus ambulatory blood pressure in the prediction of all-cause and cardiovascular mortalities. J Hypertens 2011; 29:454-459.
17. Eguchi K, Pickering TG, Hoshide S, Ishikawa J, Ishikawa S, Schwartz JE, et al. Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. Am J Hypertens 2008; 21:443-450.
18. Lekakis JP, Zakopoulos NA, Protogerou AD, Kotsis VT, Papaioannou TG, Stamatelopoulos KS, et al. Cardiac hypertrophy in hypertension: relation to 24-h blood pressure profile and arterial stiffness. Int J Cardiol 2004; 97: 29-33.
19. La Batide-Alanore A, Chatellier G, Bobrie G, Fofol I, Plouin P-F. Comparison of nurse- and physician-determined clinic blood pressure levels in patients referred to a hypertension clinic: implications for subsequent management. J Hypertens 2000; 18:391-398.
20. Coll de Tuero G, Sanmartin Albertos M, Vargas Vila S, Trè mols Iglesias S, Saez Zafra M, Barcelò Rado A. Does blood pressure change in treated hypertensive patients depending on whether it is measured by a physician or a nurse? Blood Press 2004; 13:164-168.
21. Gosse P, Ansoborlo P, Lemetayer P, Clementy J. Daytime and nighttime ambulatory blood pressures should be calculated over the true sleep/waking cycle and not over arbitrary periods. Am J Hypertens 1996; 9:269-272.
22. De Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens 2005; 18:191-196.
23. Zhang Y, Li Y, Ding FH, Sheng CS, Huang QF,Wang JG. Cardiac structure and function in relation to central blood pressure components in Chinese. J Hypertens 2011; 29:2462-2468.
24. Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, Maughan WL, et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation 1997; 95:1827-1836.
25. Pauca AL, ORourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38:932-937.
26. Sharman JE, Lim R, Qasem AM, Coombes JS, Burgess MI, Franco J, et al. Validation of a generalized transfer function to noninvasively derive central blood pressure during exercise. Hypertension 2006; 47:1203-1208.
27. Hope SA, Tay DB, Meredith IT, Cameron JD. Use of arterial transfer functions for the derivation of central aortic waveform characteristics in subjects with type 2 diabetes and cardiovascular disease. Diabetes Care 2004; 27: 746-751.
28. Agabiti-Rosei E, Mancia G, ORourke MF, Roman MJ, Safar ME, Smulyan H, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 2007; 50:154-160.
29. Hirata K, Vlachopoulos C, Adji A, ORourke MF. Benefits from angiotensinconverting enzyme inhibitor beyond blood pressure lowering: beyond blood pressure or beyond the brachial artery? J Hypertens 2005; 23: 551-556.
30. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.